Pentixapharm Announces Progress of Pivotal Phase 3 PANDA Study; Will Host Third Quarter Webcast on November 12, 2026

No FDA comments on the study protocol submitted in August 2026, including the primary endpoints and the planned number of approximately 325 patients; central U.S. ethics committee…

يعرض MarketNews العنوان والملخص كما نشرتهما الوسيلة الإعلامية. المقال الكامل متوفر على موقع الناشر. (www.prnewswire.com)